Category list : All-Wales Medicines Strategy Group
Sort by: Newest first Oldest first A-Z Z-A
-
Restrictions on prescribing OTC treatments rejected in Wales Subscription
Proposals to restrict the prescribing of medicines and other treatments that are available over the counter will not go ahead in Wales.
-
Three-year PrEP pilot begins in Wales
A trial has begun in Wales to assess the use of the antiretroviral combination treatment emtricitabine/tenofovir disoproxil (marketed as Truvada) for pre-exposure prophylaxis (PrEP) against HIV infection.
-
Treatment fund launched in Wales for newly approved drugs
An £80m new treatment fund to pay for high-cost drugs approved for use on the NHS in Wales has been launched.
-
Welsh audit body recommends managing medicines plan
The government, the NHS and health bodies should revise the indicators used to compare how different prescribers and organisations use medicines, says a report by the Welsh Audit Office.
-
Gething confirms £80m fund for high-cost medicines in Wales
A central fund worth £80m that will pay for the immediate use of new, high-cost medicines that are approved for use in Wales has been announced by Vaughan Gething, cabinet secretary for health for the Welsh government.
-
Welsh Labour pledge to create £80m central fund for high cost drugs Subscription
Welsh Labour has pledged to create an £80m central fund to pay for high cost medicines if they retain control of the National Assembly for Wales following the election on 5 May 2016.
-
January 2016: AWMSG approvals Subscription
The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use by the NHS in Wales: atazanavir/cobicistat (Evotaz) for adults infected with human immunodeficiency virus-1 (HIV-1); efavirenz (Sustiva) for children aged between 3 months and 3 years who are infected with HIV-1; macitentan (Opsumit) for adults with pulmonary arterial hypertension (only where the approved patient access scheme is used); empagliflozin (Jardiance) for type 2 diabetes. Full details ...
-
December 2015: AWMSG approvals Subscription
The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use in NHS Wales: Cetuximab (Erbitux; Merck Serono) for the first-line treatment of epidermal growth factor receptor-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or the chemotherapy regimen FOLFOX. Ivacaftor (Kalydeco; Vertex) for cystic fibrosis (CF) in patients aged 6 years and older who have mutations in the CF transmembrane ...
-
December 2015: AWSMG approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Abasaglar (a biosimilar of insulin glargine; Eli Lilly and Company) for diabetes mellitus in patients aged 2 years and above. Sucroferric oxyhydroxide (Velphoro; Vifor Fresenius Medical Care Renal Pharma) for controlling serum phosphorus levels in adults with chronic kidney disease who are on haemodialysis or peritoneal dialysis where non-calcium based ...
-
AWMSG November medicines approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Xultophy (insulin degludec and liraglutide) for use with oral antidiabetic drugs to treat adults with type 2 diabetes — it can only be used when oral treatments combined with basal insulin do not provide adequate glycaemic control; Fomicyt (fosfomycin) to treat acute osteomyelitis, complicated urinary tract infections, nosocomial lower respiratory tract infections or bacterial ...
-
August 2015: AWMSG approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): brimonidine gel for treating the symptoms of moderate-to-severe, persistent facial erythema associated with rosacea; Rezolsta (darunavir and cobicistat) for use in combination with other antiretroviral medicines to treat human immunodeficiency virus-1 infection in adults; magnesium aspartate dihydrate for treating and preventing magnesium deficiency in patients aged two ...
-
AWMSG medicines approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Darunavir, in combination with other antiretrovirals, for treating human immunodeficiency virus-1 infection in children aged at least three years and weighing 15kg and over; peginterferon beta-1a for treating adults with relapsing-remitting multiple sclerosis; regorafenib for treating adults with unresectable or metastatic gastrointestinal stromal tumours who progressed ...
-
July 2015: AWMSG approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Fostair (beclometasone/formoterol; Chiesi) inhaler for patients with chronic obstructive pulmonary disease, and Adcetris (brentuximab; Takeda) for adults with relapsed or refractory CD30+ Hodgkin lymphoma who have undergone an autologous stem cell transplant or following at least two other therapies. The drug is not recommended for treating systemic anaplastic large cell ...
-
June 2015 AWMSG approvals Subscription
Adalimumab (Humira; AbbVie) can be prescribed in NHS Wales to treat active, enthesitis-related arthritis in patients aged six years and older, following its use being approved by the All Wales Medicines Strategy Group (AWMSG). The group has not recommended dapagliflozin (Forxgia; Bristol-Myers Squibb) as monotherapy for type 2 diabetes or aflibercept (Zaltrap; Sanofi) for metastatic colorectal cancer (in combination with irinotecan, ...
-
AWMSG medicines approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): bedaquiline for pulmonary multidrug‑resistant tuberculosis in adult patients as part of an appropriate combination regimen; daclatasvir for chronic hepatitis C virus infection in adults with significant fibrosis or compensated cirrhosis (as part of combination treatment); defibrotide for severe hepatic veno-occlusive disease alongside haematopoietic stem-cell transplantation ...
-
AWMSG medicines approvals Subscription
Infliximab biosimilars Inflectra (Hospira) and Remsima (Celltrion) have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG). Both can be used for any licensed indication in accordance with AWMSG or National Institute for Health and Care Excellence guidance and should be prescribed by brand. The group has also approved lurasidone (Latuda; Sunovion) to treat adults with schizophrenia and Anoro Ellipta (umeclidinium and vilanterol; GlaxoSmithKline) to relieve ...
-
Cabozantinib and follitropin alfa recommended in Wales Subscription
Cabozantinib has been recommended for use by the All Wales Medicines Strategy Group for progressive, unresectable, locally advanced or metastatic medullary thyroid carcinoma. The group has also approved follitropin alfa for use in NHS Wales to stimulate follicular development in women: With anovulation unresponsive to clomiphene Undergoing superovulation for assisted reproduction With severe luteinising hormone and follicle-stimulating hormone deficiency It ...
-
AWMSG medicines decisions Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG) in January 2015: leuprorelin acetate as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer; umeclidinium (Incruse) and olodaterol (Striverdi Respimat) to relieve symptoms in chronic obstructive pulmonary disease; ponatinib to treat chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia, ...
-
Alogliptin approved for use in Wales Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): alogliptin, in combination with metformin or a sulphonylurea, to treat adults with type 2 diabetes (Vipdomet — a combination tablet containing metformin and alogliptin — is also approved); bortezomib, with dexamethasone, to treat adults with progressive multiple myeloma who have received at least one previous treatment and for whom haematopoietic stem ...
-
AWMSG decisions Subscription
The following medicines have not been recommended for use by the All Wales Medicines Strategy Group (AWMSG) and should not be prescribed in NHS Wales: Abiraterone (Zytiga) with prednisolone for metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic after androgen deprivation therapy (the drug is allowed for patients whose disease has progressed — as per National Institute ...
Show 10 per page20 per page50 per page
